Pharmaceutical

NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

NN-6561 is under clinical development by Novo Nordisk and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Jul 6, 2024 - 04:00
NN-6561 is under clinical development by Novo Nordisk and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Read the original article

Tags:

Previous Article

AZD-2389 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MA...

Next Article

CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (h...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and challenges ahead

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and ...

Jul 20, 2023

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biogen completes $1.15bn HI-Bio acquisition to expand i...

Jul 4, 2024

Twist rolls out TCR and CAR libraries for cell therapies development

Twist rolls out TCR and CAR libraries for cell therapie...

Apr 14, 2023